Good news! Provenge will be covered by Medicare. It’s an expensive treatment, but the panel decided it is worth it. Here is a link to Bloomberg report.

As I had mentioned in my February update, I have high hopes about this treatment (may be I am slightly biased because of my Immunology background). Analysts expect revenue of $2.4 billion at it’s peak and since Dendreon is marketing the drug itself (unlike many other Biotech companies that have to partner with a big pharma) it doesn’t have to share the profit with anyone. Dendreon is still not operating at its full capacity, but it is trying to bring all the facilities online soon.

I think Dendreon also makes a good takeover target now that they’ll generate revenue (Pfizer, GSK??)